Esperion Therapeutis.Inc. buy HC Wainwright
Summary
This prediction is currently active. With a performance of 130.42% the BUY prediction by HC_Wainwright is a big success. This prediction currently runs until 13.11.24. The prediction end date can be changed by HC_Wainwright at any time. HC_Wainwright has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | 2.389% | 2.389% |
iShares Core DAX® | 4.015% | 2.971% |
iShares Nasdaq 100 | 2.755% | 0.503% |
iShares Nikkei 225® | -0.826% | -5.057% |
iShares S&P 500 | 2.330% | 0.720% |
Comments by HC_Wainwright for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Stopped prediction by HC_Wainwright for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
08.05.24
08.05.25
19:55
Esperion Therapeutis.Inc.
25.03.24
25.03.25
19:55
Esperion Therapeutis.Inc.
28.02.24
28.02.25
19:55
Esperion Therapeutis.Inc.
28.08.23
28.08.24
19:55
Esperion Therapeutis.Inc.
06.03.23
06.03.24
07.03.24